Biogen (HAM:IDP) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 02, 2026)


HAM:IDP Biogen Inc HAM:IDP
74 GF Score
Price €186.64
GF Value €170.68
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Biogen Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Biogen's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

HAM:IDP vs OGN, AMRN, SCLX: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - General subindustry, Biogen's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biogen Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Biogen's Margin of Safety % (DCF Dividends Based) falls into.


HAM:IDP
74GF Score
Biogen Inc HAM:IDP
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biogen (HAM:IDP) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €186.64 is trading 9.4% above its estimated GF Value™ of €170.68. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for HAM:IDP:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €170.68 vs. price of €186.64 (9.4% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the HAM:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
74GF Score

Get the complete analysis for HAM:IDP

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€186.64
Price
€170.68
GF Value